Compare BioNano Genomics Inc (BNGO) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Vistra Corp — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Vistra Corp trades at $146.45 (market cap $48.64B). The key difference: Vistra Corp is far larger — about 3560.8× BioNano Genomics Inc's market cap, and Vistra Corp pays a 0.63% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | VST | |
|---|---|---|
Market Cap | $13.66M | $48.64B |
Sector | Health | Technology |
52-Week High | $4.92 | $217.92 |
52-Week Low | $1.06 | $134.71 |
Enterprise Value | $16.26M | $70.58B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
VST trades at $146.36, up 2.44% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $1.767 billion adjusted EBITDA, beating expectations, while maintaining 2026 guidance. Valuation metrics show a P/E of 24.44 and robust profitability with 75.73% ROE, though recent earnings have been inconsistent with two misses in the last four quarters.
VST presents a compelling growth story driven by data center power demand and nuclear assets, with 90.9% analyst buy ratings and a $239.75 price target suggesting 64% upside. Key risks include ERCOT pricing volatility and hedging losses, while institutional interest remains strong with recent strategic acquisitions positioning the company for AI infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
